Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review

Catalog Quick Order

Your Account

Shopping Cart

Check Out

Your Purchase Helps Fund Health Research

AIDS

Alzheimer's Disease

Arthritis

Autism

Cancer

Candida

Depression

Detoxification

Diabetes

Fibromyalgia

Heart Disease

Hormone

Irritable Bowel Syndrome

Lupus

Lyme Disease

Multiple Chemical Sensitivity

ME/Chronic Fatigue Syndrome

Migraines

Parkinson's Disease

Sinusitis

Thyroid Disease

Weight Loss

ProHealth Vitamin and Supplement Catalog

Your resource for specialty nutritional supplements, books, DVDs, resources for better living, health news & more!

Your Purchases Help Fund Ongoing Research

Search our extensive library for information, solutions & support

Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review - fibromyalgia related research

April 15, 2000

We evaluated the efficacy and tolerability of opioids in the long-term management of chronic noncancer pain. This retrospective chart review included 86 outpatients who started receiving, between 1994 and 1998, long-acting opioids. For each patient, the number of different opioids used and the efficacy and tolerability of each opioid prescribed were noted. During a mean follow-up of 8.8 +/- 6.3 mo, the number of opioids used by each patient was 2.3 +/- 1.4. Patient diagnoses were: back pain (31), neuropathy (20), joint pain (13), visceral pain (7), reflex sympathetic dystrophy (7), headache (5), fibromyalgia (3). The first opioid prescribed was effective for 36% of patients, was stopped because of side effects in 30%, and was stopped for ineffectiveness in 34%. Of the remaining patients, the second opioid prescribed after the failure of the first was effective in 31%, the third in 40%, the fourth in 56%, and the fifth in 14%. There was one case of addiction and no case of tolerance. We conclude that if it is necessary to change the opioid prescription because of intolerable side effects or ineffectiveness, the cumulative percentage of efficacy increases with each new opioid tested. Failure of one opioid cannot predict the patient's response to another. Implications: This study showed that if a patient receiving chronic opioid therapy experiences an intolerable side effect or if the drug is ineffective, changing to a different opioid may result in a lessening or elimination of the side effect and/or improved analgesia.

Quang-Cantagrel ND, Wallace MS, Magnuson SK

DISCUSS THIS ARTICLE (0 existing comments)


[ Be the first to comment on this article ]

Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review - fibromyalgia related research Article Tools

Print Page	Email Article
Discuss		Rate This

Featured Vitamins, Supplements, and Health Products

	Organic Life® Vitamins by Peter Gillham's Natural Vitality Premium daily multi-vitamin

	Fish Oil, Omega Swirl Lemon Zest by Barlean's 730 mg EPA/DHA per serving

	Moducare® Promotes increase in number of 'smart' immune cells

	Strontium Bone Maker by Doctor's Best Clinically proven help for the prevention & treatment of osteoporosis & other bone-related conditions

	GABA Quiets the brain by calming neurotransmitter overactivity



Dr. David Bell on XMRV Research: "Now We Can Get Down to Business" [more] CFS Advisory Committee Meeting - Live Online Oct 29-30 [more] Heard Through the Grapevine: Test kit for XMRV to be available from Reno-based VIP Dx [more] Dr. Charles Shepherd Updates His Advisory on Swine Flu & the Vaccine for ME/CFS Patients – A Highly ... [more] Don't Miss the New York Times Q&A on XMRV by Dr. Klimas [more]

ProHealth Vitamin and Supplement SmartSavings Club

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.